Key result
Neoadjuvant chemotherapy shows no reported impact on autonomic nervous system function during CPET.
Why the study?
Neoadjuvant chemotherapy is associated with autonomic nervous system dysfunction and must be excluded as a confounding factor when investigating contributors to postoperative vasoplegia using CPET.
Does neoadjuvant chemotherapy measurably impair autonomic nervous system function in patients undergoing oncological surgery?
Observational
No
Does neoadjuvant chemotherapy measurably impair autonomic nervous system function in patients undergoing oncological surgery?
This retrospective analysis outlines a protocol to evaluate whether neoadjuvant chemotherapy impairs autonomic nervous system function as measured by cardiopulmonary exercise testing.
Objective: Our organisation provides oncological surgery for approximately a million population. Postoperative vasoplegia is a contributor to increased length of stay. We aimed to investigate contributors to vasoplegia using cardiopulmonary exercise testing (CPET), which we perform routinely. We hypothesise that autonomic nervous system (ANS) dysfunction, measured through chronotropic responsiveness (CR) and HR recovery (HRR) during CPET, is a measurable marker. However, our patients receive neoadjuvant chemotherapy (NAC), which is associated with ANS dysfunction and must be excluded as a confounding factor.
No takes yet. Share an insight, caveat, or question.
Kermode et al. (2026) conducted an observational in Oncology surgery candidates. Neoadjuvant chemotherapy was evaluated on Autonomic nervous system dysfunction (chronotropic responsiveness and HR recovery during CPET). The effect of neoadjuvant chemotherapy on autonomic nervous system function was investigated, but no results were reported in the provided abstract.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: